Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $73.9 million.

  • Zentalis Pharmaceuticals' Total Non-Current Liabilities fell 2250.82% to $73.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.9 million, marking a year-over-year decrease of 2250.82%. This contributed to the annual value of $92.3 million for FY2024, which is 1796.62% down from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $73.9 million for Q3 2025, which was down 2250.82% from $76.7 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $112.5 million during Q4 2023, with a 5-year trough of $45.0 million in Q1 2022.
  • Over the past 4 years, Zentalis Pharmaceuticals' median Total Non-Current Liabilities value was $95.8 million (recorded in 2023), while the average stood at $92.5 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 12624.52% in 2023, then plummeted by 2897.69% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $102.7 million in 2022, then rose by 9.6% to $112.5 million in 2023, then dropped by 17.97% to $92.3 million in 2024, then decreased by 19.96% to $73.9 million in 2025.
  • Its Total Non-Current Liabilities stands at $73.9 million for Q3 2025, versus $76.7 million for Q2 2025 and $88.1 million for Q1 2025.